Ryaltris Drug Interactions

No formal drug-drug interaction studies have been performed with RYALTRIS. The drug interactions of the combination are expected to reflect those of the individual components.
In vitro studies with human liver microsomal preparations have shown that olopatadine is not an inhibitor of CYPs 1A2, 2C8/9, 2C19, 2D6, 2E1 or 3A4. Because elimination of olopatadine is predominantly by renal excretion as unchanged drug, co-administered CYP inhibitors are not expected to affect olopatadine exposure. Mometasone furoate is subject to extensive hepatic metabolism.
In vitro studies have confirmed the primary role of CYP3A4 in the metabolism of this compound. Co-administration with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, cobicistat-containing products) may lead to increased plasma concentrations of corticosteroids and potentially increase the risk for systemic corticosteroid side-effects. Consider the benefit of co-administration versus the potential risk of systemic corticosteroid effects, in which case patients should be monitored for systemic corticosteroid side-effects.